Regression models of unadjusted and adjusted age-adjusted z scores by study arm.

<p>Regression models of unadjusted and adjusted age-adjusted z scores by study arm.</p

Complications, recovery times, and neurocognitive outcome by treatment arm.

<p>Complications, recovery times, and neurocognitive outcome by treatment arm.</p

Regression models of unadjusted and adjusted age-adjusted z scores by study arm.

<p>Regression models of unadjusted and adjusted age-adjusted z scores by study arm.</p

Flowchart of study population.

<p>Flowchart of study population.</p

Differences in mean age-adjusted z scores and cognitive impairment by study arm.

<p>Differences in mean age-adjusted z scores and cognitive impairment by study arm.</p

MOESM1 of Inhaled nitric oxide as adjunctive therapy for severe malaria: a randomized controlled trial

Additional file 1. Sensitivity analyses and quality measures for clinical trial “Inhaled nitric oxide as adjunctive therapy for severe malaria”. Description: Sensitivity analyses on the primary and secondary (mortality) endpoints are provided. Measures of the quality of blinding and quality of clinical care in the trial are described

Dengue virus (DENV) hemagglutination inhibition (HAI) profiles at enrolment in different age groups.

<p>Dengue virus (DENV) hemagglutination inhibition (HAI) profiles at enrolment in different age groups.</p

Description of cohort subjects.

<p>Description of cohort subjects.</p

Proportion of dengue naïve subjects at enrolment that seroconverted at 12 months.

<p>Proportion of dengue naïve subjects at enrolment that seroconverted at 12 months.</p

Proportion of symptomatic dengue virus (DENV) infections among total (symptomatic and subclinical) DENV infections in per-protocol subjects with different DENV hemagglutination inhibition (HAI) profiles at enrolment.

<p>Negative HAI: 4/12; monotypic HAI: 2/5; multitypic HAI: 7/57 (chi-square, p = 0.068). Three symptomatic cases were not included because of missing HAI titers.</p